menu
    • menu
    [{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Cinnarizine","moa":"Voltage-gated L-type calcium channel | Histamine H1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Dr. Reddy's Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals for Stugeron Forte

    Menu

    Stugeron Forte

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Johnson & Johnson

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cinnarizine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

                            Details : The portfolio acquired includes Stugeron (cinnarizine) brand as well as its leading local brands Stugeron Forte and Stugeron Plus across 18 markets in the APAC and EMEA regions.

                            Product Name : Stugeron

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 11, 2025

                            Lead Product(s) : Cinnarizine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth